Benign Prostatic Hyperplasia Treatment Market by Type, End User and Region - Global Forecast to 2026
DUBLIN, March 29, 2021 /PRNewswire/ -- The "Benign Prostatic Hyperplasia Treatment Market by Type (Drug (Alpha Blockers(Tamsulosin, Doxazosin), 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride), Surgical Treatment (TURP, TUMT, TUNA)), End User (Hospitals) - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
- DUBLIN, March 29, 2021 /PRNewswire/ -- The "Benign Prostatic Hyperplasia Treatment Market by Type (Drug (Alpha Blockers(Tamsulosin, Doxazosin), 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride), Surgical Treatment (TURP, TUMT, TUNA)), End User (Hospitals) - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
- The global benign prostatic hyperplasia treatment market is projected to reach USD 14.1 billion by 2026 from USD 10.8 billion in 2021, at a CAGR of 5.3% from 2021 to 2026.
- Drug treatment is expected to hold the largest share of the benign prostatic hyperplasia treatment market, by type in 2021.
- On the basis of region, the benign prostatic hyperplasia treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.